Recaticimab
IIT-I-2025-098
Approved small_molecule active
Quick answer
Recaticimab for STEMI - ST Elevation Myocardial Infarction is a Approved program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- STEMI - ST Elevation Myocardial Infarction
- Phase
- Approved
- Modality
- small_molecule
- Status
- active